TITLE:
GSTP1 (Ile105Val) Gene Polymorphism: Risk and Treatment Response in Chronic Myeloid Leukemia
AUTHORS:
Shereen Elhoseiny, Mohamed El-Wakil, Mohamed Fawzy, Aya Abdel Rahman
KEYWORDS:
CML; GSTs; GSTP1 (Ile105Val)
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.5 No.1,
December
27,
2013
ABSTRACT: Background: Genetic variation influencing individual susceptibility to chemical
carcinogens is one of the main factors leading to cancer development. The
glutathione S-transferases (GSTs) are a family of enzymes belonging to phase II enzymes involved in detoxification of xenobiotics. A
significant relationship is observed between the risk of developing cancer and
genetic polymorphisms within GSTs. Methods: In this study, we investigated the influence of inherited GSTP1
(Ile105Val) gene polymorphism on the susceptibility to CML in Egypt in 40 CML
patients (20 children and 20 adults), together with 40 healthy controls using a
[PCR-RFLP] assay. Results: We
found that the mutant type (IIe/Val, Val/Val) was significantly higher in CML
patients (67.5%) compared to controls (35%) (p = 0.004); [odds ratio 3.9; 95% CI: 1.5 - 9.7]. The mutant type was associated
with more advanced phases in disease and with both worse hematological and
cytogenetic responses when compared to the wild type (p = 0.03, p = 0.05, and p 0.001, respectively). Conclusion: GSTP1 (Ile105Val) gene
polymorphism conferred a significant association with increased risk of CML and
is associated with worse prognosis. Further studies on the functional
consequences of this genetic polymorphism would pave the way to declare its
role in the pathogenesis of CML or as a possible predictor for response to
therapy.